SCHEMBL1812657

SCHEMBL1812657

NC(=O)c1ccc(C(=O)N(Cc2ncc[nH]2)Cc2ncc[nH]2)nc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.43
NNMT P40261 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KLK1 P06870 1/20 0.37
KLK5 Q9Y337 1/20 0.37
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TAAR1 Q96RJ0 3/20 0.36
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 1/20 0.34
GLA P06280 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
HPGDS O60760 1/20 0.33
P4HA1 P13674 1/20 0.33
MIF P14174 1/20 0.33
P4HTM Q9NXG6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1793716 0.85 CXCR4 (0.53) CXCR4SMN1; SMN2KLK1KLK5TAAR1
SCHEMBL1811130 0.84 CXCR4 (0.39) CXCR4SMN1; SMN2TAAR1CYP2D6TSHR
SCHEMBL1810039 0.83 CXCR4 (0.41) CXCR4NNMTSMN1; SMN2KLK1KLK5
SCHEMBL1794404 0.78 CXCR4 (0.44) CXCR4SMN1; SMN2KDM4ETAAR1CYP2D6
SCHEMBL840090 0.75 NNMT (0.45) NNMTSMN1; SMN2KDM4EL3MBTL1TSHR
SCHEMBL4607724 0.75 CXCR4 (0.47) CXCR4KDM4E
SCHEMBL1808509 0.75 CXCR4 (0.41) CXCR4SMN1; SMN2KLK1KLK5TAAR1
SCHEMBL1810957 0.74 CXCR4 (0.45) CXCR4SMN1; SMN2TAAR1CYP2D6TSHR
SCHEMBL1807966 0.74 CXCR4 (0.40) CXCR4SMN1; SMN2KLK1KLK5TAAR1
SCHEMBL14856665 0.74 TAAR1 (0.53) CXCR4SMN1; SMN2KDM4ETAAR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US disclosed
US-7951816-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2011-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CCR5, CXCL12 CXCR4 1/4885NNMT 92/4885SMN1; SMN2 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.